Abstract Details

Title Adult Absence Seizures: A Two-Center Cohort Study

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-011

Objective We aim to describe clinical and demographic characteristics of absence seizures in adults.

Background Absence seizures are characterized by sudden cessation of activity and awareness, accompanied by generalized spike-and-wave discharges (SWD) on EEG. They commonly present in childhood or adolescence; however, it can persist in adulthood and be drug-resistant.

Design/Methods An observational, descriptive, cross-sectional study in patients diagnosed with absence seizures between 2023 and 2024 from a Neurology Center in Mexico City (Mexico) and Barcelona (Spain). SPSS® 29 was used for the analysis. Quantitative variables were expressed as mean and standard deviation. Qualitative variables were expressed as frequencies and percentages.

Results We included 32 patients, 16 from Mexico City and 16 from Barcelona, of which 21 (65.6%) were female. Mean age of 43.19±13.403 (19-70) and mean age of onset of 13.8 ±6.21( 5-38). Mean months of epilepsy evolution was 29.75±14.02 (0-61). Eight(28.6%) had epilepsy family history. 25 (78.1%) patients had presented tonic-clonic generalized seizures, 16 (50%) myoclonic seizures, 3 (9.4%) palpebral myoclonic seizures, 3 (9.7%) non-epileptic seizures, and 28 (87.5%) more than one seizure type. 25 (78.1%) had MRI, 11 (34.4%) were abnormal; 3 (9.4%) had vascular lesions, 1 (3.1%) cerebellar atrophy, 3(9.4%) cortical atrophy, and 2 (6.3%) arachnoid cyst. Moreover, 12(37.5%) patients presented psychiatric comorbidities, 5 (15.6%) depression, 6(18.8%) anxiety, 2(6.3%) psychosis and 4(12.5%) intellectual disabilities. Mean of antiseizure medications was 2.9 ± 2.5 (0-11), and drug-resistant epilepsy was found in 6 (18.3%) patients. Twenty (62.5%) patients were absence-free, and 21 (65.6%) were free from other types of seizures.

Conclusions Epilepsy with absence seizures can continue into adulthood, in this cohort women were more affected, family history was present in one-third of patients and generalized tonic-clonic seizures were present in most patients. Having an abnormal MRI was common and less than 20% of patients were drug-resistant

Authors/Disclosures
Irving Fuentes PRESENTER	Mr. Fuentes has nothing to disclose.
Mijail A. Rivas, Sr., MD (Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Juarez)	Dr. Rivas has nothing to disclose.
Jimena Gonzalez Salido, MD	Miss Gonzalez Salido has nothing to disclose.
Luis A. Marin-Castañeda, Sr. (INNN)	Mr. Marin-Castañeda has nothing to disclose.
Jimena Colado, MD	Dr. Colado has nothing to disclose.
Fernando Vasquez Lopez, MD	Dr. Vasquez Lopez has nothing to disclose.
Betsy C. Vazquez, MD	Dr. Vazquez has nothing to disclose.
Eithel A. Valenzuela Mendivil	Eithel A. Valenzuela Mendivil has nothing to disclose.
Salvador Martinez-Medina, MD	Dr. Martinez-Medina has nothing to disclose.
Manuel Toledo	Manuel Toledo has nothing to disclose.
Manuel Quintana, Sr., PhD	Mr. Quintana has nothing to disclose.
Laura Abraira del Fresno, MD, PhD	Dr. Abraira del Fresno has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB pharma. Dr. Abraira del Fresno has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals. Dr. Abraira del Fresno has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini. Dr. Abraira del Fresno has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EISAI.
Elena Fonseca, MD, PhD	Dr. Fonseca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Fonseca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz Pharmaceuticals. Dr. Fonseca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Fonseca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals. Dr. Fonseca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini Pharma.
Andrea Avalos Arias, MD	Dr. Avalos Arias has nothing to disclose.
Aurelio J. Prado, PhD	Prof. Prado has nothing to disclose.
Adriana Ochoa, PhD	Dr. Ochoa has nothing to disclose.
Jorge L. Guerrero, Sr., PhD	Dr. Guerrero has nothing to disclose.
Mario Sebastian-Diaz, MD, PhD	Dr. Sebastian-Diaz has nothing to disclose.
Iris E. Martinez-Juarez, MD (Instituto Nacional de Neurología y Neurocirugía)	No disclosure on file

��ɫ��

��ɫ��